To the Editor In their systematic review and meta-analysis, Scott and colleagues1 concluded that the practice of placebo run-in (PRI) periods in randomized clinical trials (RCTs) of antidepressants should be discontinued. They examined 174 studies of major depressive disorder that used single-blind PRI designs and found less robust within-group changes in both the experimental drug and placebo groups and equivalence in the drug-placebo outcome differences compared with studies that did not use PRI designs.
Targum SD. Do Not Rule Out Double-blind Placebo Run-in Periods for Randomized Clinical Trials. JAMA Psychiatry. 2022;79(4):381. doi:10.1001/jamapsychiatry.2022.0048
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.